AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03008889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63.
Trial: NCT03319797
Drug: NOVOCART® Inject plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
Trial: NCT03833661
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
Trial: NCT04239586
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting treatment with sulfonylurea class of drug
Trial: NCT00255983
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets BID for 5 days
Trial: NCT02296905
Drug: ABT-493
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
Trial: NCT02296905
Drug: ABT-530
RxNorm normalized name: ABT-925
DrugBank: ABT-560 (DB06093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
Trial: NCT00142285
Drug: Zinc sulphate (20 mg)
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03702647
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mL of normal saline placed in the POEM tunnel
Trial: NCT04086966
Drug: [68Ga]PSMA-PET/MRI or PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]PSMA-PET/MRI or PET/CT
Trial: NCT01699152
Drug: TG02 citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG02 citrate capsules
Trial: NCT03993704
Drug: LHF-535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension administered once daily for 14 days
Trial: NCT00854061
Drug: T-Pred
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT00780104
Drug: Rapamycin + MEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
Trial: NCT01278394
Drug: AN2690 Solution, 5.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 360 days
Trial: NCT00857649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets Once Daily
Trial: NCT02974660
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03975049
Drug: FOLFOXIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
Trial: NCT03975049
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
Trial: NCT00581854
Drug: modified Hyper-CVAD
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
Trial: NCT01378676
Drug: Placebo (Part B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily for 14 days (Part B)
Trial: NCT02049294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02158091
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous chemotherapy
Trial: NCT00220272
Drug: SR57667B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03494270
Drug: Rosuvamibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10mg/Ezetimibe 10mg
Trial: NCT03494270
Drug: Monorova
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20mg
Trial: NCT01336933
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00085163
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00085163
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00085163
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00293657
Drug: Lornoxicam 8 mg
RxNorm normalized name: lornoxicam 8 MG
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00293657
Drug: Lornoxicam 16 mg
RxNorm normalized name: Lornoxicam 16 mg prolonged-release oral tablet
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00293657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00788307
Drug: liothyronine sodium
RxNorm normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03917797
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
Trial: NCT03917797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC infusion vehicle
Trial: NCT03324490
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neuro-axially injected
Trial: NCT01366001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual administration, Placebo administered once daily for 10 consecutive days.
Trial: NCT01239511
Drug: green tea polyphenols (STA-2)
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules t.i.d., after meal
Trial: NCT01677689
Drug: Apomivir®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
Trial: NCT03012360
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
Trial: NCT01677689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
Trial: NCT01169025
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
Trial: NCT01259141
Drug: Cephalosporins and azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
Trial: NCT03467347
Drug: VR: 200 mg DPV + 320 mg LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
Trial: NCT01328769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04655690
Drug: NNC0471-0119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
Trial: NCT00556075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily for 4 months
Trial: NCT02428777
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive oral diclofenac 100 mg 1 hour before the procedure
Trial: NCT02428777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo 1 hour before the procedure
Trial: NCT05006235
Drug: Epinephrine Inhalation Solution
RxNorm normalized name: Epinephrine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05006235
Drug: Saline Inhalants
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02107833
Drug: OPRX-106
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02521168
Drug: Oral triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triiodothyronine is given peri-operatively through naso-gastric tube
Trial: NCT02521168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consist of saccharin lactis that has the same appearance as Tetronine
Trial: NCT01666990
Drug: TwHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
Trial: NCT01666990
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
Trial: NCT01800097
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
Trial: NCT00176839
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
Trial: NCT03833154
Drug: (Osimertinib cohort, single-arm, open-label separate cohort)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
Trial: NCT00158028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo match in identical tablets
Trial: NCT03534869
Drug: Analgesics
RxNorm normalized name: ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
Trial: NCT02689180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacement of furosemide by placebo
Trial: NCT00035490
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet, once daily for one year
Trial: NCT00465192
Drug: estradiol, 10 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00465192
Drug: estradiol, 25 mcg
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00465192
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01662986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day (QD)
Trial: NCT01215786
Drug: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
Trial: NCT01666704
Drug: Placebo matching with BMS-823778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0mg, Once daily, 1 year
Trial: NCT04682483
Drug: Vasopressor
RxNorm normalized name: Vasopressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
Trial: NCT01215786
Drug: AGN-207281 vehicle ophthalmic solution (Placebo)
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
Trial: NCT03339258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, or inactive pill.
Trial: NCT00065260
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
Trial: NCT02962258
Drug: Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, crossover
Trial: NCT02962258
Drug: Tribenzor of Daichi Sankyo Inc. USA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, crossover
Trial: NCT03372785
Drug: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
Trial: NCT03314493
Drug: Spironolactone 25Mg Tablet
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months
Trial: NCT03715517
Drug: Bupicavaine 0.125% epidural solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
Trial: NCT00432484
Drug: Lingzhi and Sen Miao San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
Trial: NCT02040623
Drug: R348 Ophthalmic Solution, 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
Trial: NCT02040623
Drug: R348 Ophthalmic Solution, 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
Trial: NCT04085991
Drug: 131I-PSMA-1095 Radioligand Therapy (RLT)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
Trial: NCT00111085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Trial: NCT00796549
Drug: BiBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 in EGFR FISH positive NSCLC patients
Trial: NCT01275105
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop in each eye at designated visits
Trial: NCT03281694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo skin patch and placebo oral solution
Trial: NCT02617199
Drug: intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
Trial: NCT03310645
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 different doses over the course of study
Trial: NCT03310645
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for BAY1817080
Trial: NCT00867867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.3 mg once per day, 6 days per week, for 9 months
Trial: NCT03475524
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebos will be given to control beside trichloracetic acid peeling
Trial: NCT03475524
Drug: Trichloroacetic Acid Peeling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichloroacetic acid peeling to the three groups
Trial: NCT01208818
Drug: Cyclophosphamide + Bortezomib + Dexamethasone regimen
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect.
Trial: NCT01198275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of olive oil,one capsule twice a day
Trial: NCT00905450
Drug: BOL-303242-X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
Trial: NCT00905450
Drug: Vehicle for BOL-303242-X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication instilled into the study eye, subjects randomized to various drug dose schedules.
Trial: NCT00665665
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for s.c. injection
Trial: NCT03007966
Drug: Epinephrine 1:200k
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as part of the local anesthetic mixture
Trial: NCT03601780
Drug: usual care only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual care only
Trial: NCT03041948
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT03041948
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT03041948
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT01387594
Drug: lumbar puncture
RxNorm normalized name: Lumbar Puncture 18g 3.5"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
Trial: NCT01695460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04369586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02176538
Drug: Product 0405
RxNorm normalized name: Pyelocalyceal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product 0405 will be administered topically twice daily for 28 days
Trial: NCT02176538
Drug: Placebo for Product 0405
RxNorm normalized name: placebo Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Product 0405 will be administered topically twice daily for 28 days.
Trial: NCT00553683
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01426269
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
Trial: NCT01426269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
Trial: NCT02461264
Drug: Single red blood packed cells Transfusion
FDA approved: no
EMA approved: no
PMDA approved: no